Yamada Takahiro, Takemura Yoshizumi, Niisato Naomi, Mitsuyama Etsuko, Iwasaki Yoshinobu, Marunaka Yoshinori
Department of Molecular Cell Physiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.
Biochem Biophys Res Commun. 2009 Mar 13;380(3):586-90. doi: 10.1016/j.bbrc.2009.01.122. Epub 2009 Jan 25.
We report the effects of new N-acylated ambroxol derivatives (TEI-588a, TEI-588b, TEI-589a, TEI-589b, TEI-602a and TEI-602b: a, aromatic amine-acylated derivative; b, aliphatic amine-acylated derivative) induced from ambroxol (a mucolytic agent to treat human lung diseases) on Cl(-) secretion in human submucosal serous Calu-3 cells under a Na(+)/K(+)/2Cl(-) cotransporter-1 (NKCC1)-mediated hyper-secreting condition. TEI-589a, TEI-589b and TEI-602a diminished hyper-secretion of Cl(-) by diminishing the activity of NKCC1 without blockade of apical Cl(-) channel (TEI-589a>TEI-602a>TEI-589b), while any other tested compounds including ambroxol had no effects on Cl(-) secretion. These indicate that the inhibitory action of an aromatic amine-acylated derivative on Cl(-) secretion is stronger that that of an aliphatic amine-acylated derivative, and that 3-(2,5-dimethyl)furoyl group has a strong action in inhibition of Cl(-) secretion than cyclopropanoyl group. We here indicate that TEI-589a, TEI-589b and TEI-602a reduce hyper-secretion to an appropriate level in the airway, providing a possibility that the compound can be an effective drug in airway obstructive diseases including COPD by reducing the airway resistance under a hyper-secreting condition.
我们报告了氨溴索(一种用于治疗人类肺部疾病的黏液溶解剂)衍生的新型N-酰化氨溴索衍生物(TEI-588a、TEI-588b、TEI-589a、TEI-589b、TEI-602a和TEI-602b:a,芳香胺酰化衍生物;b,脂肪胺酰化衍生物)在Na(+)/K(+)/2Cl(-)共转运体-1(NKCC1)介导的高分泌条件下对人黏膜下浆液性Calu-3细胞中Cl(-)分泌的影响。TEI-589a、TEI-589b和TEI-602a通过降低NKCC1的活性而减少Cl(-)的高分泌,而不阻断顶端Cl(-)通道(TEI-589a>TEI-602a>TEI-589b),而包括氨溴索在内的任何其他测试化合物对Cl(-)分泌均无影响。这些结果表明,芳香胺酰化衍生物对Cl(-)分泌的抑制作用强于脂肪胺酰化衍生物,并且3-(2,5-二甲基)糠酰基比环丙酰基在抑制Cl(-)分泌方面具有更强的作用。我们在此表明,TEI-589a、TEI-589b和TEI-602a可将气道中的高分泌降低至适当水平,这为该化合物通过在高分泌条件下降低气道阻力而成为包括慢性阻塞性肺疾病(COPD)在内的气道阻塞性疾病的有效药物提供了可能性。